AstraZeneca has agreed to acquire to CinCor Pharma for $26.00 per share in cash plus a contingent value right of $10.00 per share in cash payable upon a specified regulatory submission of a baxdrostat product.
Related: South Korean Regulator Fines AstraZeneca and Local Firm for Collusion
Marc de Garidel, Chief Executive Officer at CinCor, said: “We are excited about the proposed acquisition of CinCor Pharma by AstraZeneca as we believe it offers the prospect of accelerating the development timeline and expanding the breadth of benefits patie.
